Trials / Completed
CompletedNCT02135536
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM282 | NGM282 |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2014-05-12
- Last updated
- 2017-03-28
Locations
17 sites across 3 countries: United States, Australia, New Zealand
Source: ClinicalTrials.gov record NCT02135536. Inclusion in this directory is not an endorsement.